Lanthanum carbonate

Drugs of Today

Volumn 42, Issue 12, 2006, Pages 759-770

  Freemont, A J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; SEVELAMER; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; BINDING AFFINITY; BONE MINERALIZATION; BRONCHITIS; CALCIUM TRANSPORT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; DIALYSIS GRAFT COMPLICATION; DIALYSIS GRAFT OCCLUSION; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAFT DYSFUNCTION; GRAFT OCCLUSION; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOMAGNESEMIA; HYPOTENSION; KIDNEY FUNCTION; METABOLIC ACIDOSIS; NAUSEA; NONHUMAN; OSTEOMALACIA; REVIEW; RHINITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; BONE AND BONES; CLINICAL TRIALS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; TRACE ELEMENTS;

EID: 33846973342     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.12.1025698     Document Type: Review

References (64)

1. Rutherford, E., Mercado, A., Hruska, K. et al. An evaluation of a new and effective phosphorus binding agent. Trans Am Soc Artif Intern Organs 1973, 19: 446-9.
2. Slatopolsky, E., Rutherford, W.E., Rosenbaum, R., Martin, K., Hruska, K. Hyperphosphatemia. Clin Nephrol 1977, 7: 138-46.
3. Marsden, S.N., Parkinson, I.S., Ward, M.K., Ellis, H.A., Kerr, D.N. Evidence for aluminium accumulation in renal failure. Proc Eur Dial Transplant Assoc 1979, 16: 588-96.
4. Alfrey, A.C., LeGendre, G.R., Kaehny, W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976, 294: 184-8.
5. Malluche, H.H., Faugere, M.C. Aluminum-related bone disease. Blood Purif 1988, 6: 1-15.
6. Kerr, D.N., Ward, M.K., Arze, R.S. et al. Aluminum-induced dialysis osteodystrophy: The demise of 'Newcastle bone disease'? Kidney Int 1986, 18: S58-64.
7. Gonzalez-Revalderia, J., Casares, M., de Paula, M., Pascual, T., Giner, V., Miravalles, E. Biochemical and hematological changes in low-level aluminum intoxication. Clin Chem Lab Med 2000, 38: 221-5.
8. Wills, M.R., Savory, J. Aluminium poisoning: Dialysis encephalopathy, osteomalacia, and anaemia. Lancet 1983, 2: 29-34.
9. Freemont, A.J., Denton, J. Demonstration of aluminium on bone using different staining techniques and spectrophotometry. J Clin Pathol 1989, 42: 671-2.
10. Malluche, H.H., Monier-Faugere, M.C. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992, 38: S62-67.
11. Mai, M.L., Emmett, M., Sheikh, M.S., Santa Ana, C.A., Schiller, L., Fordtran, J.S. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989, 36: 690-5.
12. Hercz, G., Kraut, J.A., Andress, D.A. et al. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 1986, 12: 314-9.
13. Slatopolsky, E., Weerts, C., Stokes, T., Windus, D., Delmez, J. Alternative phosphate binders in dialysis patients: Calcium carbonate. Semin Nephrol 1986, 6: 35-41.
14. Goodman, W.G. Vascular calcification in chronic renal failure. Lancet 2001, 358: 1115-6.
15. Martin, K.J., Gonzalez, E.A. Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001, 38: 1430-6.
16. Sheikh, M.S., Maguire, J.A., Emmett, M. et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989, 83: 66-73.
17. Guillot, A.P., Hood, V.L., Runge, C.F., Gennari, F.J. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982, 30: 114-7.
18. Oe, P.L., Lips, P., van der Meulen, J., de Vries, P.M., van Bronswijk, H., Donker, A.J. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 1987, 28: 180-5.
19. O'Donovan, R., Baldwin, D., Hammer, M., Moniz, C., Parsons, V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1986, 1: 880-2.
20. Delmez, J.A., Kelber, J., Norword, K.Y., Giles, K.S., Slatopolsky, E. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 1996, 49: 163-7.
21. Moriniere, P., Vinatier, I., Westeel, P.F. et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988, 3: 651-6.
22. Gonella, M., Ballanti, P., Della Rocca, C. et al. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 1988, 14: 240-5.
23. Slatopolsky, E.A., Burke, S.K., Dillon, M.A. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999, 55: 299-307.
24. Chertow, G.M., Burke, S.K., Dillon, M.A., Slatopolsky, E. Long-term effects of sevelamer hydrochloride on the calciumxphosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999, 14: 2907-14.
25. Ferramosca, E., Burke, S., Chasan-Taber, S., Ratti, C., Chertow, G.M., Raggi, P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005, 149: 820-5.
26. Qunibi, W.Y., Hootkins, R.E., McDowell, L.L. et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004, 65: 1914-26.
27. Savica, V., Calò, A., Monardo, P., Santoro, D., Bellinghieri, G. Phosphate binders and management of hyperphosphataemia in end-stage renal disease Nephrology Dialysis Transplantation 2006, 21: 2065-8.
28. Graft, L., Burnel, D. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol 1995, 89: 373-88.
29. Bingham, D., Dobrota, M. Binding of lanthanides to cell membranes in the presence of ligands. J Inorgan Biochem 1995, 59: 39-52.
30. Damment, S.J., Totten, W. The pharmacology of a new phosphate binder, lanthanum carbonate. Nephrol Dial Transplant 2003, 18: 683.
31. Emmett, M., Hootkins, R. Phosphorus binders. In: Nissenson, A.R., Fine R.N. (Eds.). Dialysis Therapy. Hanley & Belfus, Philadelphia, 1993, 293-6.
32. Hutchison, A.J. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004, 19 (Suppl. 1): 19-24.
33. Behets, G.J., Gritters, M., Dams, G., De Broe, M.E., D'Haese, P.C. Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 2005, 27: 475-84.
34. Graft, L., Burnel, D. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol 1995, 89: 373-88.
35. Fiddler, G., Stewart, A.J., Sack, M. Overview of the pharmacokinetics of lanthanum carbonate (Fosrenol®): A non-aluminum, non-calcium phosphate binder. J Am Soc Nephrol 2003, 14: 205.
36. Drueke, T.B. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 2002, 17 (Suppl. 2): 13-16.
37. Behets, G.J., Dams, G., Damment, S., D'Haese, P.C., De Broe, M.E. An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model. J Am Soc Nephrol 2001, 12: 740.
38. Yang, Z., Schryvers, D., Roels, F., D'Haese, P.C., De Broe, M.E. Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 2006, 223: 133-9.
39. Behets, G.J., Verberckmoes, S.C., D'Haese, P.C., De Broe, M.E. Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 2004, 13: 403-9.
40. Behets, G.J, Verberckmoes, S.C., Oste, L. et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005, 67: 1830-6.
41. Freemont, A.J., Hoyland, J.A., Denton, J.; Lanthanum Carbonate SPD405-303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005, 64: 428-37.
42. Pennick, M., Dennis, K., Damment, S. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006, 46: 738-46.
43. Stewart, J. Administration of a novel phosphate binder, Fosrenol, with food is associated with good tolerability and low systemic absorption. J Am Soc Nephrol 2002, 13: 386A.
44. Stewart, A.J. Fosrenol® - A novel non-calcium, non-aluminum phosphate binder is well tolerated when given during or after food intake. J Am Soc Nephrol 2002, 13: 751.
45. Sack, M., Brunner, L.J., Frazer, N. Fosrenol® (lanthanum carbonate) is well tolerated in patients requiring hemodialysis: Results of a phase I clinical trial. Poster presented at the 35th Meeting of the American Society of Nephrology, Philadelphia 2002.
46. Hutchison, A.J., Maes, B., Vanwalleghem, J. et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract 2006, 102: 61-71.
47. Shire Pharmaceuticals Development Ltd. Product monograph. FOSRENOL® - Summary of the product characteristics. Available at http://www.pbm.va.gov/monograph/q97846 Lanthanum%20Carb.pdf.
48. Yokel, R.A., McNamara, P.J. Aluminium toxicokinetics: An updated minireview. Pharmacol Toxicol 2001, 88: 159-67.
49. Al-Baaj, F., Speake, M., Hutchison, A.J. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005, 20: 775-82.
50. D'Haese, P.C., Spasovski, G.B., Sikole, A. et al. A multicenter study on the effects of lanthanum carbonate (Rosrenol®) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003, 63 (Suppl. 85): 73-8.
51. Joy, M.S., Finn, W.F. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003, 42: 96-107.
52. Finn, W.F., Joy, M.S., Hladik, G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004, 62: 193-201.
53. Hutchison, A.J., Speake, M., Al-Baaj, F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004, 19: 1902-6.
54. Hutchison, A.J., Maes, B., Vanwalleghem, J. et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clinical Practice 2005, 100: c8-19.
55. Chiang, S.S., Chen, J.B., Yang, W.C. Lanthanum carbonate (Fosrenol®) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005, 63: 461-70.
56. Finn, W.F., Joy, M.S. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005, 21: 657-64.
57. Finn, W.F. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006, 65: 191-202.
58. Huybrechts, K.F., Caro, J.J., Wilson, D.A., O'Brien, J.A. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value in Health 2005, 8: 549.
59. See Highmark/Blue Shield Web site: http://highmark.formularies.com/ drug_disp.asp ?category=Diagnostic+%26+Miscellaneous+ Agent&subcategory= Miscellaneous+Agents
60. Fosrenol® prescribing information. Available at: http://www.fosrenol.com/PDFs/PrescribingInfo. pdf
61. Joy, M.S., Kshirsagar, A., Candiani, C., Brooks, T., Hudson, J.Q. Lanthanum Carbonate. Ann Pharmacother 2006, 40: 234-40.
62. Finn, W.F., Joy, M.S., Webster, I. Lanthanum carbonate vs standard therapy in hyperphosphatemia: Interim findings from a 2-year safety and outcomes study. J Am Soc Nephrol 2003, 14: 764A.
63. Malluche, H.H., Marwad, H. Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future direction. Nephrol Dial Transplant 2002, 17: 1170-5.
64. Freemont, T., Malluche, H.H. Utilization of bone histomorphometry in renal osteodystrophy: Demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005, 63: 138-45.